Neogen Corporation Cost of Revenue
Neogen Corporation (NEOG) reported Cost of Revenue of $473.29 million for the 12-month period ending 2025-05-31, per its 10-K filed 2025-07-30.
Financial Statements › Expense Statement › Cost of Sales
us-gaap:CostOfRevenue · last filed 2025-07-30
- Neogen Corporation cost of revenue for the quarter ending 2018-02-28 was $50.37M, a 6.03% increase year-over-year.
- Neogen Corporation cost of revenue for the quarter ending 2017-11-30 was $52.55M, a 11.50% increase year-over-year.
- Neogen Corporation cost of revenue for the quarter ending 2017-08-31 was $49.38M, a 14.41% increase year-over-year.
- Neogen Corporation cost of revenue for the quarter ending 2017-05-31 was $51.83M, a 7.47% increase year-over-year.
- Neogen Corporation cost of revenue for fiscal 2025 was $473.29M, a 2.82% increase from fiscal 2024.
- Neogen Corporation cost of revenue for fiscal 2024 was $460.32M, a 10.52% increase from fiscal 2023.
- Neogen Corporation cost of revenue for fiscal 2023 was $416.49M.
- Neogen Corporation cost of revenue for fiscal 2017 was $189.63M, a 12.73% increase from fiscal 2016.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2025-05-31 | $473.29M 10-K · filed 2025-07-30 | |||
| 2024-05-31 | $460.32M 10-K · filed 2025-07-30 | |||
| 2023-05-31 | $416.49M 10-K · filed 2025-07-30 | |||
| 2018-02-28 | $50.37M 10-Q · filed 2018-03-29 | $102.92M derived: sum of 2 quarters · filed 2018-03-29 | $152.30M 10-Q · filed 2018-03-29 | $204.13M derived: sum of 4 quarters · filed 2018-03-29 |
| 2017-11-30 | $52.55M 10-Q · filed 2018-01-05 | $101.93M 10-Q · filed 2018-01-05 | $153.76M derived: sum of 3 quarters · filed 2018-01-05 | $201.26M derived: sum of 4 quarters · filed 2018-03-29 |
| 2017-08-31 | $49.38M 10-Q · filed 2017-09-29 | $101.21M derived: sum of 2 quarters · filed 2017-09-29 | $148.72M derived: sum of 3 quarters · filed 2018-03-29 | $195.84M derived: sum of 4 quarters · filed 2018-03-29 |
| 2017-05-31 | $51.83M derived: 10-K 12 month − 10-Q 9 month · filed 2017-07-28 | $99.33M derived: sum of 2 quarters · filed 2018-03-29 | $146.46M derived: sum of 3 quarters · filed 2018-03-29 | $189.63M 10-K · filed 2017-07-28 |
| 2017-02-28 | $47.51M 10-Q · filed 2018-03-29 | $94.63M derived: sum of 2 quarters · filed 2018-03-29 | $137.80M 10-Q · filed 2018-03-29 | $186.02M derived: sum of 4 quarters · filed 2018-03-29 |
| 2016-11-30 | $47.13M 10-Q · filed 2018-01-05 | $90.29M 10-Q · filed 2018-01-05 | $138.52M derived: sum of 3 quarters · filed 2018-01-05 | $180.05M derived: sum of 4 quarters · filed 2018-01-05 |
| 2016-08-31 | $43.17M 10-Q · filed 2017-09-29 | $91.39M derived: sum of 2 quarters · filed 2017-09-29 | $132.92M derived: sum of 3 quarters · filed 2017-09-29 | $174.31M derived: sum of 4 quarters · filed 2017-09-29 |
| 2016-05-31 | $48.23M derived: 10-K 12 month − 10-Q 9 month · filed 2017-07-28 | $89.75M derived: sum of 2 quarters · filed 2017-07-28 | $131.14M derived: sum of 3 quarters · filed 2017-07-28 | $168.21M 10-K · filed 2017-07-28 |
| 2016-02-29 | $41.53M 10-Q · filed 2017-03-31 | $82.92M derived: sum of 2 quarters · filed 2017-03-31 | $119.98M 10-Q · filed 2017-03-31 | $160.90M derived: sum of 4 quarters · filed 2017-07-28 |
| 2015-11-30 | $41.39M 10-Q · filed 2016-12-29 | $78.45M 10-Q · filed 2016-12-29 | $119.37M derived: sum of 3 quarters · filed 2017-07-28 | $154.07M derived: sum of 4 quarters · filed 2017-07-28 |
| 2015-08-31 | $37.07M 10-Q · filed 2016-09-30 | $77.98M derived: sum of 2 quarters · filed 2017-07-28 | $112.69M derived: sum of 3 quarters · filed 2017-07-28 | $146.93M derived: sum of 4 quarters · filed 2017-07-28 |
| 2015-05-31 | $40.91M derived: 10-K 12 month − 10-Q 9 month · filed 2017-07-28 | $75.62M derived: sum of 2 quarters · filed 2017-07-28 | $109.87M derived: sum of 3 quarters · filed 2017-07-28 | $143.39M 10-K · filed 2017-07-28 |
| 2015-02-28 | $34.71M 10-Q · filed 2016-03-31 | $68.95M derived: sum of 2 quarters · filed 2016-03-31 | $102.48M 10-Q · filed 2016-03-31 | $137.70M derived: sum of 4 quarters · filed 2016-07-29 |
| 2014-11-30 | $34.25M 10-Q · filed 2016-01-08 | $67.77M 10-Q · filed 2016-01-08 | $102.99M derived: sum of 3 quarters · filed 2016-07-29 | $134.28M derived: sum of 4 quarters · filed 2016-07-29 |
| 2014-08-31 | $33.52M 10-Q · filed 2015-09-30 | $68.75M derived: sum of 2 quarters · filed 2016-07-29 | $100.04M derived: sum of 3 quarters · filed 2016-07-29 | $130.15M derived: sum of 4 quarters · filed 2016-07-29 |
| 2014-05-31 | $35.22M derived: 10-K 12 month − 10-Q 9 month · filed 2016-07-29 | $66.52M derived: sum of 2 quarters · filed 2016-07-29 | $96.62M derived: sum of 3 quarters · filed 2016-07-29 | $124.81M 10-K · filed 2016-07-29 |
| 2014-02-28 | $31.29M 10-Q · filed 2015-04-01 | $61.40M derived: sum of 2 quarters · filed 2015-04-01 | $89.58M 10-Q · filed 2015-04-01 | $117.21M derived: sum of 4 quarters · filed 2015-07-30 |
| 2013-11-30 | $30.11M 10-Q · filed 2014-12-30 | $58.29M 10-Q · filed 2014-12-30 | $85.92M derived: sum of 3 quarters · filed 2015-07-30 | $109.66M derived: sum of 4 quarters · filed 2015-07-30 |
| 2013-08-31 | $28.18M 10-Q · filed 2014-09-30 | $55.81M derived: sum of 2 quarters · filed 2015-07-30 | $79.55M derived: sum of 3 quarters · filed 2015-07-30 | $102.98M derived: sum of 4 quarters · filed 2015-07-30 |
| 2013-05-31 | $27.63M derived: 10-K 12 month − 10-Q 9 month · filed 2015-07-30 | $51.37M derived: sum of 2 quarters · filed 2015-07-30 | $74.80M derived: sum of 3 quarters · filed 2015-07-30 | $98.03M 10-K · filed 2015-07-30 |
| 2013-02-28 | $23.74M 10-Q · filed 2014-04-04 | $47.17M derived: sum of 2 quarters · filed 2014-04-04 | $70.41M 10-Q · filed 2014-04-04 | |
| 2012-11-30 | $23.43M 10-Q · filed 2014-01-09 | $46.67M 10-Q · filed 2014-01-09 | ||
| 2012-08-31 | $23.23M 10-Q · filed 2013-09-30 | |||
| 2012-05-31 | $91.62M 10-K · filed 2014-07-30 | |||
| 2011-05-31 | $84.89M 10-K · filed 2013-07-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |